Sage Therapeutics Inc (SAGE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sage Therapeutics Inc (SAGE) has a cash flow conversion efficiency ratio of -0.159x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-58.69 Million) by net assets ($368.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sage Therapeutics Inc (SAGE) liquidity interval to measure how many days the company can operate on defensive assets alone.
Sage Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Sage Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sage Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sage Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kura Sushi USA Inc
NASDAQ:KRUS
|
0.003x |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212
|
N/A |
|
Jiangsu Yueda Investment Co Ltd
SHG:600805
|
0.002x |
|
Luoyang Glass
SHG:600876
|
0.003x |
|
BIOCYTOGEN PHARMA. H YC1
F:I54
|
N/A |
|
Gifore Agricultural Machinery Chain Co Ltd
SHE:300022
|
-0.017x |
|
Hanwha General
KO:000370
|
0.202x |
|
Bridgewater Bancshares Inc
NASDAQ:BWB
|
0.030x |
Annual Cash Flow Conversion Efficiency for Sage Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Sage Therapeutics Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see SAGE company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $465.09 Million | $-267.19 Million | -0.575x | +15.03% |
| 2023-12-31 | $799.53 Million | $-540.59 Million | -0.676x | -84.10% |
| 2022-12-31 | $1.25 Billion | $-460.04 Million | -0.367x | -67.91% |
| 2021-12-31 | $1.73 Billion | $-378.18 Million | -0.219x | -168.23% |
| 2020-12-31 | $2.07 Billion | $664.28 Million | 0.321x | +157.27% |
| 2019-12-31 | $944.65 Million | $-528.71 Million | -0.560x | -85.29% |
| 2018-12-31 | $862.97 Million | $-260.67 Million | -0.302x | +34.50% |
| 2017-12-31 | $475.48 Million | $-219.28 Million | -0.461x | -43.20% |
| 2016-12-31 | $368.52 Million | $-118.68 Million | -0.322x | +20.86% |
| 2015-12-31 | $173.69 Million | $-70.68 Million | -0.407x | -83.41% |
| 2014-12-31 | $121.89 Million | $-27.04 Million | -0.222x | -139.94% |
| 2013-12-31 | $-31.54 Million | $-17.52 Million | 0.555x | -16.65% |
| 2012-12-31 | $-13.39 Million | $-8.93 Million | 0.666x | -- |
About Sage Therapeutics Inc
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric m… Read more